Darbepoetin Alfa Articles
Amgen initiates Ph III Aranesp study in HF
12 September 2005
Amgen's Aranesp gives 77% response in MDS
18 July 2005
Amgen submits sBLA for Aranesp
16 May 2005
Amgen posts 26% EPS hike, raises forecast
25 April 2005
IMS: 2004 world Rx sales growth slowest in six yrs
14 March 2005
Amgen adds safety warning to Aranesp
24 January 2005
Biogenerics to command more than $12B by 2010
17 January 2005
Aranesp OKed for extended dosing in EU
27 September 2004
Aranesp on track for extended dosing in EU
16 August 2004
Amgen's 2nd-qtr 2004 EPS jumps 27%
9 August 2004
Amgen's EPS for 1st-qtr 2004 jumps 36%
3 May 2004
J&J's sales leap 17.7% for 1st-qtr 2004
19 April 2004
FDA to view Aranesp and Procrit in May
29 March 2004
Strong sales boost Amgen profit
2 February 2004
Amgen forecasts 18%-30% rise in 2004 profits, boosted by lead drugs
22 December 2003
US Medicare bill and biotech reimbursement
15 December 2003
Improving the treatment of anemia in cancer, discussed at ECCO
20 October 2003
Amgen outperforms in 1st qtr, raises forecast
28 April 2003
Stock Commentary - New York
29 July 2002
New use for Amgen's Aranesp OKed in USA
29 July 2002
Aranesp gets CPMP backing for two drugs
10 June 2002
Amgen's Aranesp beats J&J's Procrit
3 June 2002
Stock Commentary - New York
6 May 2002
FDA approves Amgen's new-generation filgrastim product, Neulasta
11 February 2002
Fresenius snubs J&J in favor of Amgen
28 January 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Stock Commentary - New York
6 December 2001
J&J adds warning to Eprex labeling
6 December 2001
Amgen expecting strong sales and earnings growth in 2002
22 November 2001
Amgen third-quarter earnings up 5%
29 October 2001
Aranesp filed in EU for chemotherapy use
25 October 2001
Stock Commentary - New York
27 September 2001
Japanese pharma stocks - week to September 24
26 September 2001
Amgen files for Aranesp in cancer anemia
21 September 2001
Amgen's Aranesp gets clearance in USA for renal anemia
19 September 2001
Amgen pulls out of Plenaxis alliance
19 September 2001
Stock Commentary - New York
13 September 2001
Amgens sales/income growth slows in 2Q01
2 August 2001
Stock Commentary - New York
14 June 2001
Aranesp equivalent to Epogen in Ph III trial
15 May 2001
Stock Commentary - New York
3 May 2001
Amgen's 1st-qtr net income rises 15%
1 May 2001
Amgen notes delay in launch of Aranesp
1 May 2001
Amgen wins patent suit against TKT in UK
18 April 2001
CPMP backs approval of Amgen's Aranesp
20 March 2001
Amgen net income falls 25% in 4th qtr
30 January 2001
Stock Commentary - New York
2 November 2000
Epogen sales slowing at Amgen
1 November 2000
First cancer data for Amgen's Aranesp
19 October 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
